Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells

Foidart, Jean‐Michel; Colin, Claude; Denoo, Xavier; Desreux, Jean F.; Béliard, Aude; Fournier, S.; Lignières, B. De

doi:10.1016/s0015-0282(98)00042-9

Cited by 139 publications

(73 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Progesterone's role in breast cancer is controversial. It has been hypothesized that its activity of opposing estrogenic stimulation of the breast decreases breast cancer risk [6]. On the other hand, some believe that the risk of breast cancer is increased because breast mitotic rates are highest in the luteal (high progesterone) phase of the menstrual cycle [7].…”

Section: Discussionmentioning

confidence: 99%

Role of Some Risk Factors in the Etiology of Breast Cancer in the Sudan

Ahmed¹,

Musa²,

Eltybe³

et al. 2014

TOBCANJ

View full text Add to dashboard Cite

Abstract:Aim: The aim of this study was to correlate breast cancer by common breast cancer risk factors in the Sudan.Methodology: Using a purposeful questionnaire 150 female breast cancer patients and 100 apparently health controls were asked detailed information on about risk factors.Results: Out of the 150 women with breast cancer, 38 (25.3%), 22(14.7%), 26(17.3%), 20(13.3%), 21(14%), 11(7.3%), 72(48%), and 86(57.3%) were identified as having a previous history of oral contraceptives usage, a family history of breast cancer, a past history of benign breast disease, a previous history of breast cancer, a previous breast biopsy, claimed other cancers in their families, confessed a pesticides exposure, and over weigh in most of their lives respectively. Out of the 150 women, 44(29.3%) were found to have a previous physical activity. Moreover, 44.8% and 66.9% have attended the menarge at the age of 13 and 14 respectively. Of these factors, statistical significant risks were found with, past history of benign breast disease (P < 0.04), previous breast biopsies (P <0.07), pesticides and plasticizers exposure (P < 0.01 and 0.04), period of being over weight (P <0.001), practice physical activities (P <0.0001), unmarried (P <0.002), decreased number of children (P <0.002). According to the ethnic group, Gaalyaeen tribes represented 61(40.7%) of the study subjects. Most of the patients were from Khartoum state, constituting 37.3%. Conclusion:There was variable exposure to many risk factors for breast cancer in the Sudan. The study suggests further separate measurement of risk factors for breast cancer, as well as, factors that might reduce those risk factors. Cohort mean of evaluation is highly recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Some Risk Factors in the Etiology of Breast Cancer in the Sudan

Ahmed¹,

Musa²,

Eltybe³

et al. 2014

TOBCANJ

View full text Add to dashboard Cite

show abstract

“…[23][24][25][26] The only epidemiological study comparing the impact of progesterone and synthetic progestins on the breast was the PEPI trial, 27 in which the authors assessed differences between placebo and several HRTs on the change in mammographic percent density. Our result of breast cancer risk significantly greater with HRT containing synthetic progestins than with HRT containing micronized progesterone, at least for short durations of use (Ͻ 4 years), is therefore new.…”

Section: Discussionmentioning

confidence: 99%

Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort

Fournier

Berrino

Riboli

et al. 2004

Intl Journal of Cancer

350

189

View full text Add to dashboard Cite

Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. A recent large cohort study showed effects of similar magnitude for different types of progestogens and for different routes of administration of estrogens evaluated. Further investigation of these issues is of importance. We assessed the risk of breast cancer associated with HRT use in 54,548 postmenopausal women who had never taken any HRT 1 year before entering the E3N-EPIC cohort study (mean age at inclusion: 52.8 years); 948 primary invasive breast cancers were diagnosed during follow-up (mean duration: 5.8 years). Data were analyzed using multivariate Cox proportional hazards models. In this cohort where the mean duration of HRT use was 2.8 years, an increased risk in HRT users compared to nonusers was found (relative risk (

show abstract

“…(39) observaram que a administração de progesterona por 14 dias reduziu a proliferação celular induzida pelo estradiol. Este grupo advoga que os baixos índices de PCNA encontrados no grupo que usou TRHM combinando estrogênio e progesterona podem refletir a capacidade da progesterona em manter as células epiteliais na fase G1 do ciclo celular.…”

Section: Discussionunclassified

“…A progesterona, então, participaria na regulação da proliferação celular das células epiteliais da mama. Sendo assim, a progesterona administrada via percutânea, poderia ter um valor terapêutico, antagonizando os efeitos proliferativos estradiol induzidos, quando aplicados por 14 dias na mama (39).…”

Section: Discussionunclassified

See 1 more Smart Citation

Expressão dos fatores de proliferação celular PCNA e Ki-67 e receptores de estrogênio e progesterona em tecido mamário normal de mulheres na pós-menopausa submetidas a dois esquemas de terapia de reposição hormonal

Marinheiro

Graudenz²,

Recktenvald³

et al. 2003

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOForam colhidas amostras de tecido mamário de 32 mulheres saudáveis na pós-menopausa: 19 utilizaram esquema cíclico de estrogênio e progestágeno (estrogênios conjugados 0,625mg, 21 dias por mês, associados ao acetato de medroxiprogesterona, 5mg, nos últimos 12 dias) e 13 tomaram apenas estrogênios (estrogênios conjugados, 0,625mg, 21 dias por mês), todas durante 6 meses consecutivos. Foram realizadas biópsias mamárias antes e ao final dos 6 meses de tratamento. A análise imunohistoquímica foi feita com anticorpos anti-PCNA do tipo PC-10, anti-Ki-67 do tipo MIB-1, anti-receptor de estrogênio do tipo 1-D5 e anti-receptor de progesterona do tipo 1-A6. Não houve diferença significativa para os fatores de mediação (receptores) no grupo que utilizou o esquema cícli -co (RE: P = 0,326; RP: P = 0,228). No grupo que utilizou apenas estrogênio, obteve-se um valor de P próximo ao limite de significância estatística para o RP (P = 0,053), mas não para o RE (P = 0,203). Com relação aos fatores de proliferação celular, não foi encontrada diferença estatisticamente significativa para o PCNA em ambos os grupos (esquema cícli -co: P = 0,121; estrogênio isolado: P = 0,208). Houve tendência para elevação do Ki-67 no grupo que fez uso de estrogênio apenas (P = 0,084), o que não se observou no grupo que fez uso de esquema cíclico (P = 0,776). Estes resultados sugerem que a associação de progestágeno à terapia estrogênica nesse grupo de mulheres pós-menopausa, pode ter contribuído para uma possível redução na expressão do receptor de progesterona e a proliferação celular, estimada pelo marcador Ki-67, agindo como um fator moderador de proliferação celular. Novos estudos são necessários para comprovar esta hipótese. Mammary tissue samples were collected from 32 healthy post menopausal women: 19 were using estrogen and progestagen on a cyclical schedule (conjugated estrogens, 0.625mg, for 21 days/month, associated to medroxyprogesterone acetate, 5mg, for the last 12 days) and 13 were using estrogen-only, on a 21 days/month schedule (conjugated estrogens, 0.625mg), all during 6 consecutive months. Biopsies were performed on the external left-hand upper quadrant before and after 6 months of treatment. Immunohystochemical analysis was performed with the antibodies: anti-PCNA of the PC-10 type, anti KI-67 of the MIB-1 type, anti ER (Estrogen Receptor) of the 1-D5 type and anti-PR (Progesterone Receptor) of the 1-A6 type. No significant differences were observed for the mediation factors in the group using the cyclical schedule (ER: P = 0.326; PR: P = 0.228). In the estrogen-only group, a P value near the statistical probability limit was found for the PR (P = 0.053) but not for ER (P = 0.203). No significant statistical difference was found for the cellular proliferation factor PCNA in both treatment groups (cyclical schedule: P = artigo original

show abstract

Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells

Cited by 139 publications

References 22 publications

Role of Some Risk Factors in the Etiology of Breast Cancer in the Sudan

Role of Some Risk Factors in the Etiology of Breast Cancer in the Sudan

Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort

Expressão dos fatores de proliferação celular PCNA e Ki-67 e receptores de estrogênio e progesterona em tecido mamário normal de mulheres na pós-menopausa submetidas a dois esquemas de terapia de reposição hormonal

Contact Info

Product

Resources

About